Expected earnings - Provectus Biopharmaceuticals Inc
Source: US Earnings Reports
Provectus Biopharmaceuticals Inc (PVCT) is expected to report for Q2 2025
Provectus Biopharmaceuticals Inc
NASDAQ: PVCT
PVCT Trading
-3.42% G/L:
$0.0508 Last:
10,557 Volume:
$0.05076 Open:
PVCT Latest News
October 09, 2025 08:00:00 am
Provectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy
September 29, 2025 08:00:00 am
Provectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer
PVCT Stock Data
$17,063,363
358,498,736
0.31%
4
1821793%
Biotechnology & Life Sciences
Healthcare
US
Knoxville
